CB · Verdict

A summary of rules, not a profit forecast — don’t buy just because of a green verdict.

• ▼ P/E 12.8 vs peer median 10.5 — more expensive than peers
• ▼ P/S 2.2 — expensive for this stock (over 10 y: from 1.8 to 2.2)
• ▼ P/S 2.2 vs peer median 1.6 — more expensive than peers
• ▼ EV/EBITDA 11.5 vs peer median 7.6 — more expensive than peers
• ▼ FCF yield 9.2% — expensive for this stock (over 4 y: from 10.2% to 14.2%)
• ▼ FCF yield 9.2% vs peer median 19.5% — more expensive than peers

• ▲ Has raised its dividend 17 years in a row
• ▲ Piotroski 6/7 — strong financial health
• ▲ Net margin rose: 12.2% → 17.2%
• ▲ Debt / equity 0.23 — moderate debt
• ▲ Free cash flow positive every year

• ▲ Revenue grows 10.8% per year (5 y)
• ▲ Earnings per share grows 26.9% per year (5 y)
• ▲ Analysts raised the earnings forecast by +5.2% in 90 days

• ▲ Price above SMA200 — long-term uptrend
• ▲ SMA50 above SMA200 — trend up
• ▲ Over a year +31% vs S&P 500 +11% — stronger than the market

• ▲ Max drawdown in the period -20% — shallow

• ▲ Consensus of 23 analysts — buy
• ▲ Insiders buying over 6 mo

• ▲ S&P 500 above SMA200 — the market is in an uptrend
• ▲ Sector (XLF) above SMA200 — in an uptrend